Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 2364 clinical trials
featured
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft Versus-Host Disease

A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft Versus-Host Disease

stem cell transplantation
stem cell transplant
bone marrow transplant
transplant conditioning
nutritional supplement
  • 300 views
  • 08 Dec, 2020
  • 1 location
featured
A Phase 2, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial of Brexpiprazole (1 - 3 mg/day) as Monotherapy or as Combination Therapy in the Treatment of Adults with Post-traumatic Stress Disorder

A Phase 2, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial of Brexpiprazole (1 - 3 mg/day) as Monotherapy or as Combination Therapy in the Treatment of Adults with Post-traumatic Stress Disorder

  • 1376 views
  • 23 Nov, 2020
  • 1 location
featured
A Multicenter, Open-Label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First Line Treatment of Subjects with Advanced Renal Cell Carcinoma

A Multicenter, Open-Label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First Line Treatment of Subjects with Advanced Renal Cell Carcinoma

  • 220 views
  • 08 Nov, 2020
  • 1 location
featured
FINCH 1: A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

FINCH 1: A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

  • 818 views
  • 23 Nov, 2020
  • 1 location
featured
LUX-Lung IO: A phase II, open label, non-randomised study of afatinib in combination with pembrolizumab in patients with locally advanced or metastatic squamous cell carcinoma of the lung

LUX-Lung IO: A phase II, open label, non-randomised study of afatinib in combination with pembrolizumab in patients with locally advanced or metastatic squamous cell carcinoma of the lung

lung cancer
alopecia
squamous cell carcinoma
chemoradiotherapy
metastatic squamous cell carcinoma
  • 538 views
  • 24 Nov, 2020
  • 1 location
featured
Type 2 Diabetes Study – Seeking Volunteers Who Treat with Any Combination of Medications, Except Insulin.

We are currently seeking volunteers who are diagnosed with Type 2 Diabetes and who are treating with any combination of medications including any of the following: Metformin Sulfonylureas (Glyburide, Glipizide, or Glimepiride.) Glinides (Prandin or Starlix.) DPP-4 inhibitors (Januvia, Onglyza, Tradjenta, or Nesina.) SLGT-2 inhibitors (Farxiga, Invokana, or Jardiance.) TZDs …

diabetes type 2
type 2 diabetes mellitus
type 2 diabetes
diabetes
diabetes mellitus (dm)
  • 0 views
  • 25 Jan, 2021
  • 1 location
featured
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer

A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer

cancer antigen 125
cancer of the ovary
carboplatin
ovarian cancer
paclitaxel
  • 88 views
  • 23 Nov, 2020
  • 1 location
featured
A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

  • 144 views
  • 08 Nov, 2020
  • 1 location
featured
A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non Small Cell Lung Cancer

A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non Small Cell Lung Cancer

  • 314 views
  • 23 Nov, 2020
  • 4 locations
featured
A Randomized, Open Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® with DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

A Randomized, Open Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® with DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  • 644 views
  • 08 Nov, 2020
  • 5 locations